MA
Maze Therapeutics, Inc.
MAZE · NASDAQ
$22.52 -3.84% (-$0.90)
1M -23.92%
Market Cap $1.25B
P/E Ratio -
Div. Yield -
ROE 34.94%
Piotroski F-Score Weak
3/9Valuation
36 /100
Fair P/B 2.75x
P/S 62.32x
EV/FFO N/A
Growth
100 /100
Growing Book val. growth 51.82%
FCF growth N/A
EPS growth N/A
Profitability
20 /100
Weak Op. margin 728.06%
Gross margin 95.29%
FCF margin 534.20%
Quality
0 /100
Poor ROA 25.13%
ROIC 28.35%
Asset turnover 0.04x
Debt
69 /100
Low Int. coverage -73.34x
Debt/Equity 0.13x
Current ratio 18.31x
Stability
1 /100
Unstable Profitable years 0
Beta 2.16x
EPS volatility 2,355.06%
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre MAZE
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jason Coloma
Employees
141
Headquarters
South San Francisco
Evenimente viitoare
05 NOV.
Earnings
Upcoming earnings report